CN1923171B - Compound recipe anti-cancer drugs slow release agent comprising anticancer antibiotics and synergist thereof - Google Patents

Compound recipe anti-cancer drugs slow release agent comprising anticancer antibiotics and synergist thereof Download PDF

Info

Publication number
CN1923171B
CN1923171B CN200610200171A CN200610200171A CN1923171B CN 1923171 B CN1923171 B CN 1923171B CN 200610200171 A CN200610200171 A CN 200610200171A CN 200610200171 A CN200610200171 A CN 200610200171A CN 1923171 B CN1923171 B CN 1923171B
Authority
CN
China
Prior art keywords
tumor
antitumor antibiotic
injection
slow
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200610200171A
Other languages
Chinese (zh)
Other versions
CN1923171A (en
Inventor
孙娟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Lanjin Pharmaceuticals Co Ltd
Original Assignee
Jinan Kangquan Medicine Science and Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Kangquan Medicine Science and Technology Co Ltd filed Critical Jinan Kangquan Medicine Science and Technology Co Ltd
Priority to CN200610200171A priority Critical patent/CN1923171B/en
Publication of CN1923171A publication Critical patent/CN1923171A/en
Application granted granted Critical
Publication of CN1923171B publication Critical patent/CN1923171B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

Disclosed is a compound anticancer slow release agent which comprises slow release microspheres and dissolvent, wherein the slow release microballoons comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being specific dissolvent containing suspension adjuvant. The anticancer effective ingredients include Aclarubicin, Idarubicin, Doxorubicin, Epirubicin, Valtaxin, Pirarubicin, Losaxantrone, Losoxantrone and/or anticancer antibiotic synergistic agents selected from phosphoinositide-3-kinase inhibitor, pyrimidine analogues and / or DNA restoration enzyme inhibitor, the slow release auxiliary materials are selected from polylactic acid copolymer EVAc, or sebacic acid copolymer, the viscosity of the suspension adjuvant is 100-3000cp (at 20-30 deg C). The slow release microspheres can also be prepared into slow release implanting agent for lowering down the whole body toxicity reaction of the medicament when locally dispensing on the tumor, and for selectively increasing the tumor local medicinal concentration.

Description

The compound anti-cancer medicinal slow release agent of anticancer antibiotics and synergist thereof
(1) technical field
The present invention relates to a kind of compound anti-cancer sustained-release antibiotic preparation, belong to technical field of pharmaceuticals.Particularly, the invention provides a kind of compound anti-cancer medicinal slow release agent that contains antitumor antibiotic and synergist thereof, be mainly slow releasing injection and sustained-release implant.
(2) background technology
Treatment for cancer still mainly comprises methods such as operation, radiotherapy and chemotherapy at present.Therefore wherein operative treatment can not be removed the oncocyte that is dispersed in, and often recurs or causes tumor cell to stimulate diffusion transfer because of operation; Radiotherapy and traditional chemotherapy are not had a selectivity, and be difficult to tumor by local and form effective drug level or therapeutic dose, weak effect, toxicity is big, improves the restriction that medicine or radiological dose are subjected to general toxic reaction again merely.Referring to " placing cisplatin adding system carmustine treatment rat brain tumor in the tumor " " surgery tumor magazine " 69 phase 76-82 pages or leaves (1998) (Kong Q et al., J Sur Oncol.1998Oct such as Kong Qingzhongs; 69 (2): 76-82).
The local placement of chemotherapeutics can overcome above defective preferably, not only can obviously improve the drug level of tumor by local, and can significantly reduce general toxic reaction.A large amount of internal and external tests have demonstrated the therapeutic effect to entity tumor, referring to " placing cisplatin adding system carmustine treatment rat brain tumor in the tumor " " surgery tumor magazine " 69 phase 76-82 pages or leaves (1998) (Kong Q et al., J Surg Oncol.1998Oct such as Kong Qingzhongs; 69 (2): 76-82) and Kong Qingzhong etc. " place cisplatin in the tumor and cure the former carbuncle in the occipital region tumor of rat " " surgery tumor magazine " 64 phase 268-273 pages or leaves (1997) (Kong Q et al., JSurg Oncol.1997Oct; 64:268-273).Also can be referring to Chinese patent (ZL00111093.4; ZL96115937.5; Application number 001111264,001111272) and U.S.'s patent of invention (patent No. 6,376,525B1; 5,651,986; 5,626,862).
Yet, entity tumor is made up of tumor cell and mesenchyma stroma of tumors, wherein the blood vessel in the mesenchyma stroma of tumors not only provides support and requisite nutrient substance for the growth of tumor cell, also influenced chemotherapeutics around tumor and the infiltration in the tumor tissues and diffusion (carry and to wait " situation of extracellular matrix to entity tumor in the medicine influence of turning round " " cancer research " 60 phase 2497-503 page or leaf (2000) (Netti PA referring to the Buddhist nun, Cancer Res.2000,60 (9): 2497-503)).Moreover, the blood vessel in the mesenchyma stroma of tumors often causes the enhancing of tumor cell to the toleration of cancer therapy drug to conventional chemotherapy medicine and insensitive, consequently treatment failure.
In addition, the cancer drug therapy of low dosage not only can increase the Drug tolerance of cancerous cell, but also can promote its infiltrative growth "; referring to beam etc. " increased the Drug tolerance of human lung carcinoma cell and external wetting capacity after the cancer therapy drug pulse screening and with the change of gene expression " " international journal of cancer " 111 phase 484-93 page or leaf (2004) (Liang Y; etal., Int J Cancer.2004; 111 (4): 484-93).
Therefore, develop a kind of effective cancer therapy drug or Therapeutic Method and just become a current important topic.The present invention provides a kind of new anticancer pharmaceutical composition just at the deficiencies in the prior art, can suppress growth of tumour cell effectively, and can strengthen the treatment tumor effect of other medicines, reduces recurrence.
(3) summary of the invention
The present invention is directed to the deficiencies in the prior art, a kind of compound anti-cancer sustained-release antibiotic preparation is provided.Particularly, the invention provides a kind of anticancer medicine slow-release preparation containing that contains antitumor antibiotic and/or its synergist, be mainly slow releasing injection and sustained-release implant.
Antitumor antibiotic is mainly used in entity tumors such as treatment ovarian cancer, pulmonary carcinoma abroad as a kind of new cancer therapy drug.Yet tangible general toxicity has greatly limited the application of this medicine in application process.
The present invention finds that medicine that has and antitumor antibiotic share its antitumaous effect is strengthened mutually, below the antitumor antibiotic antitumaous effect will be increased mutually medicine be referred to as the antitumor antibiotic synergist; In addition, antitumor antibiotic or antitumor antibiotic synergist are made drug level that anticancer medicine slow-release preparation containing (being mainly slow releasing injection and sustained-release implant) not only can greatly improve tumor by local, reduce the drug level of medicine in blood circulation, are reduced the toxicity of medicine to normal structure, can also greatly make things convenient for the medicine injection, reduce operation technique complication, reduce patient's expense.The above unexpected main contents of the present invention of finding to constitute.
A kind of form of antitumor antibiotic slow releasing agent of the present invention is a slow releasing injection, is made up of sustained-release micro-spheres and solvent.Particularly, this slow-releasing anticarcinogen injection is grouped into by following one-tenth:
(A) sustained-release micro-spheres comprises:
Anticancer effective component 0.5-60%
Slow-release auxiliary material 40-99%
Suspending agent 0.0-30%
More than be weight percentage
With
(B) solvent is for common solvent or contain the special solvent of suspending agent.
Wherein,
Anticancer effective component is antitumor antibiotic and/or its synergist, and the antitumor antibiotic synergist is selected from phosphoinositide 3-kinase (PI3K) inhibitor, pyrimidine analogue and/or DNA repairase inhibitor; Slow-release auxiliary material is selected from polifeprosan, bis-fatty acid and decanedioic acid copolymer (PFAD-SA)], one of copolymer (PLGA), xylitol, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, gelatin and white tempera of poly-(erucic acid dimer-decanedioic acid) [P (EAD-SA)], poly-(fumaric acid-decanedioic acid) [P (FA-SA)], ethylene vinyl acetate copolymer (EVAc), polylactic acid (PLA), polyglycolic acid and hydroxyacetic acid or its combination; Suspending agent is selected from one of sodium carboxymethyl cellulose, (iodine) glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40 and soil temperature 80 or its combination.
Above antitumor antibiotics is selected from bleomycin, daunomycin, amycin, triferricdoxorubicin, epirubicin, 7-O-methyl Nuo Jia-4 '-epirubicin, diethoxy acetyl amycin, ametycin, actinomycin D, nocardin, nocardorubin., 2-[N-(2-amidinoethyl)carbamoyl, nogalamycin, Mitochromine mitocromine B-35251, polymyxin E, pirlimycin, dirithromycin, antramycin, peplomycin, puromycin, sparsomycin, anthramycin, Carrninomycin I, puromycin, aclarubicin, aklavine-B, darubicin, Diacetoxysciroenol, clarithromycin, 9-[4-(N-Methylacetamido)anilino, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star and salt thereof, as, but be not limited to sulfate, phosphate, hydrochlorate, Lactobionate, acetate, aspat, nitrate, citrate, purine or pyrimidine salt, succinate or maleate.
Above-mentioned antitumor antibiotic shared ratio in compositions is decided because of concrete condition, can be 0.1%-50%, is good with 1%-40%, and 2%-30% is best.
Pyrimidine analogue is selected from 2,4,5-triamido-6-benzyloxy pyrimidine (2,4,5-triamino-6-benzyloxypyrimidine), 2,4-diaminourea-6-benzyloxy-5-nitroso-group pyrimidine (2,4-diamino-6-benzyloxy-5-nitrosopyrimidine), 2,4-diaminourea-6-benzyloxy-5-nitro-pyrimidine (2,4-diamino-6-benzyloxy-5-nitropyrimidine, DBNP), 2,4-diaminourea-6-benzyloxy-5-bromo pyrimidine (2,4-diamino-6-benzyloxy-5-bromopyrimi dine), 2-amino-4-benzyloxy-5-nitro-pyrimidine (2-Amino-4-benzyloxy-5-nitropyrimidine, ABNP), 2-amino-4-benzyloxy-6-methyl-5-nitro pyrimidine (2-Amino-4-benzyloxy-6-methyl-5-nitropyrimidine, ABMNP), 2,4-diaminourea-6-benzyloxy-s-triazine (2,4-Diamino-6-benzyloxy-s-triazine), 2-amino-O4-benzyl pteridine (2-amino-O4-benzylpteridine), 2-amino-O4-benzyl-6,7-diformazan pteridine (2-amino-O4-benzyl-6,7-dimethylpteridine), 2-amino-O4-benzyl-6-methylol pteridine (2-amino-O4-benzyl-6-hydroxymethylpteridine), 2-amino-O4-benzyl pteridine-6-carboxylic acid (2-amino-O4-benzylpteridine-6-carboxylic acid), 2-amino-O4-benzyl-6-formyl pteridine (2-amino-O4-benzyl-6-formylpteridine), O4-benzyl folic acid (O4-benzylfolic acid, O4-BA), 5-iodo-2 '-deoxyguanosine (5-Iodo-2 ' deoxyuridine, IDOU), 5-bromo-2 '-deoxyguanosine (5-bromo-2 '-deoxyuridine, BDOU), 4-amino-6-benzyl oxygen-5-nitro-pyrimidine (4-amino-6-benzyloxy-5-nitropyrimidine), 2,4-diaminourea-6-benzyloxy pyrimidine (2,4-diamino-6-benzyloxypyrimidine), N2-2-amino-4-chloro-5-nitro-pyrimidine (2-Amino-4-chloro-5-nitropyrimidine), in 2-amino-6-chloro-8-trifluoromethyl pyrimidine (2-Amino-6-chloro-8-trifluoromethylpurine) one or more, wherein, preferred O4-benzyl folic acid, 2,4,5-triamido-6-benzyloxy pyrimidine, 2,4-diaminourea-6-benzyloxy-5-nitroso-group pyrimidine, 2,4-diaminourea-6-benzyloxy-5-bromo pyrimidine, 2-amino-4-benzyloxy-5-nitro-pyrimidine, 2-amino-4-benzyloxy-6-methyl-5-nitro pyrimidine, 2,4-diaminourea-6-benzyloxy-s-triazine, one or more of 2-amino-O4-benzyl pteridine.
Phosphoinositide 3-kinase (phosphoinositide 3-kinase, abbreviation PI3K) inhibitor is selected from 7-hydroxy-star shaped spore native (7-hydroxyl-staurosporine, UCN-01), 7-O-alkyl-star shaped spore native (UCN-02), the beta-methoxy-star shaped spore native, alkyl phosphate choline (alkylphosphocholines), hexa-decyl choline phosphate (hexadecylphosphocholine, MIL, HPC, Miltefosine), octadecyl-(1, the 1-dimethyl-4-piperidine) (Octadecyl-(1 for phosphate, 1-dimethyl-4-piperidylio) phosphate, perifosine, D-21266), 1-O-six decyls-2-O-methyl-rac-glyceryl-3-phosphocholine (AMG-PC, 1-O-hexadecyl-2-O-methyl-rac-glycero-3-phosphocholine, ET-16-OCH3), 1-O-octadecyl-2-O-methyl-rac-glyceryl-3-phosphocholine (1-O-Octadecyl-2-O-methyl-rac-glycerophosphocholine, ET-18-OCH3, edelfosine) and 1-O-octadecyl-2-O-methyl-sn-glyceryl-3-phosphocholine (1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine, ilmofosine, L-ET-18-OCH (3)), inositolpolyphosphates (inositol polyphosphates), cyclosporin A (CyclosporinA), basic phosphocholine (the Tetradecylphosphocholine of 14 (alkane), TPC), six certain herbaceous plants with big flowers base phosphoric acid (N-N-N-trimethyl) hexanol amine (hexadecylphospho (N-N-N-trimethyl) hexanolamine, HPC6), D 19391 (octadecylphosphocholine, OPC) or octadecyl-[2-(N-methyl piperidine) ethyl]-phosphate (octadecyl-[2-(N-methylpiperidinio) ethyl]-phosphate, D-20133 or OMPEP).With 7-hydroxy-star shaped spore native, 7-O-alkyl-star shaped spore native, the beta-methoxy-star shaped spore native, alkyl phosphate choline, hexa-decyl choline phosphate, octadecyl-(1, the 1-dimethyl-4-piperidine) phosphate, 1-O-six decyls-2-O-methyl-rac-glyceryl-3-phosphocholine, 1-O-octadecyl-2-O-methyl-rac-glyceryl-3-phosphocholine, 1-O-octadecyl-2-O-methyl-sn-glyceryl-3-phosphocholine, inositolpolyphosphates, cyclosporin A, the basic phosphocholine of 14 (alkane), six certain herbaceous plants with big flowers base phosphoric acid (N-N-N-trimethyl) hexanol amine, D 19391 or octadecyl-[2-(N-methyl piperidine) ethyl]-phosphate is preferred.
DNA repairase inhibitor also can be the kinases inhibitor (DNA-dependent protein kinase (DNA-PK) inhibitors) that DNA-relies on, as, but be not limited to, imidazopyrazine (imidazopyrazine), imidazopyridine (imidazopyridine), wortmannin (wortmannin, WM), .alpha.-5:6-benzopyran (benzochromenone, NU7026), 2-(morphol-4-yl)-.alpha.-5:6-benzopyran-4-base (2-(morpholin-4-yl)-benzo[h] chomen-4-one), 6-aromatic radical-2-morphol-4-base-4H-pyrans-4-base (6-aryl-2-morpholin-4-yl-4H-pyran-4-ones), 6-aromatic radical-2-morphol-4-base-4H-thiapyran-4-base (6-aryl-2-morpholin-4-yl-4H-thiopyran-4-ones), 2-(4-Lin Ji)-8-phenylchromone (2-(4-morpholinyl)-8-phenyl chromone, LY294002), 2-(4-Lin Ji)-8-phenyl-4H-1-.alpha.-5:6-benzopyran-4-1 (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one, MPB), 1-(2-hydroxyl-4-morphol-4-base-phenyl)-ethano-) (1-(2-hydroxy-4-morpholin-4-yl-phenyl)-ethanone, HMPE), inhibitors of kinases (SU11752), vanillin (vanillin, 3-methoxy-4-hydroxybenzaldehyde), 2-aminopurine (2-Aminopurine, 2-AP), 7-ethyl-10-hydroxycamptothecine (SN-38,7-ethyl-10-hydroxycamptothecin), 3-cyano group-6-hydrazono-methyl-5-(4-pyridine radicals) pyridine-[1H]-2-1 (3-cyano-6-hydrazonomethyl-5-(4-pyridyl) pyrid-[1H]-2-one, OK-1035), phenylbutyric acid salt (Phenylbutyrate, PB), methylamine (methylamine, MA), methoxamine (methoxyamine, cefuroxime, MX), hydroxylamine (hydroxyamine, HX), minocycline (minocycline, MC), O-hydroxylamine (O-hydroxymine, OHX), O-methyl hydroxylamine (O-methylhydroxylamine, MHX), O-δ-ammonia oxygen-butyl hydroxylamine (O-delta-aminooxybutylhydroxylamine, AOHX)
DNA repairase inhibitor also can be poly-(ADP-ribose) AG14361 (poly (ADP-ribose) polymerase-1 inhibitor), be selected from 3-aminobenzamide (3-aminobenzamide, 3-AB), Benzoylamide (benzamide), 3,4-dihydro methoxy isoquinolin-1 (2H)-Benzoylamide (3,4-dihydro-5-methoxyisoquinolin-1 (2H)-one, PD 128763), AG14361 (AG14361), poly polymerase inhibitor (GPI 15427), the amino 2-aromatic radical benzimidazole-4-carboxamides BZ1-6 (2-arylbenzimidazole-4-carboxamide) that replaces, benzimidazole-4-carboxamides BZ1-6 (benzimidazole-4-carboxamides, BZ1-6), tricyclic lactam hydrogen sulfide (tricyclic lactam indoles, TI1-5), three ring benzimidazole carboxylic acid amides (tricyclicbenzimidazole carboxamide, TBC), benzimidazole (benzimidazole), 1H-three ring benzimidazole carboxylic acid amides (1H-Benzimidazole-4-carboxamides, BC), 2-aromatic radical-1H-benzimidazole-4-carboxamides BZ1-6 (2-aryl-1H-benzimidazole-4-carboxamides, ABC), 2-phenyl-1H-benzimidazole-4-carboxamides BZ1-6 (2-phenyl-1H-benzimidazole-4-carboxamide, PBC), 2-(4-hydroxymethyl phenyl)-1H-benzimidazole-4-carboxamides BZ1-6 (2-(4-hydroxymethylphenyl)-1H-benzimidazole-4-carboxamide, HMPBC), 2-(3-anisyl)-1H-benzimidazole-4-carboxamides BZ1-6 (2-(3-methoxyphenyl)-1H-benzimidazole-4-carboxamide, MPBC), 8-hydroxy-2-methyl quinazolinone (NU1025,8-hydroxy-2-methylquinazolin-4-one), 2-(4-hydroxyphenyl) benzimidazole-4-carboxamides BZ1-6 [NU1085,2-(4-hydroxyphenyl) benzamidazole-4-carboxamide].
DNA repairase inhibitor also can be glutathione synthesis inhibitor, be selected from glutathione bisulphide, tetramethylthiuram disulfide, aminotriazole(ATA) (Aminotriazole, AT), DL-Buthionine-(S,R)-sulfoximine BSO [DL-Buthionine-(S, R)-sulfoximine, be called for short BSO], acidum ethacrynicum (EA), curcumin, cavatic acid (cavatic acid), S-hexyl glutathion, new podophyllotoxin (GL331), N-[2-(dimethylamino) ethyl] and acridine-4-carboxylic acid amides (N-[2-(dimethylamino) ethyl] acridine-4-carboxamide, DACA, XR5000), 6-[2-(dimethylamino) ethylamino-]-3-hydroxyl-7H-indenols [2,1-c] chinol-7-dihydrochloride (6-[2-(dimethylamino) ethylamino]-3-hydroxy-7H-indeno[2,1-c] quinolin-7-one dihydrochloride, TAS-103), two-dioxo piperazine propane (bis-dioxopiperazine propane, ICRF 159), Exatecan mesylate (DX-8951f, exatecan mesylate), TAN-1518 (TAN-1518) etc.
DNA repairase inhibitor can be kinases inhibitor and/or poly-(ADP-ribose) AG14361 that above-mentioned any DNA-relies on, but with imidazopyrazine, imidazopyridine, wortmannin, .alpha.-5:6-benzopyran, 6-aromatic radical-2-morphol-4-base-pyrans-4-base, 2-(4-Lin Ji)-8-phenylchromone, 7-ethyl-10-hydroxycamptothecine, 3-cyano group-6-hydrazono-methyl-5-(4-pyridine radicals) pyridine-[1H]-2-1, phenylbutyric acid, methoxamine, hydroxylamine, 7-hydroxy-star shaped spore native, 7-O-alkyl-star shaped spore native, the beta-methoxy-star shaped spore native, alkyl phosphate choline, hexa-decyl choline phosphate, octadecyl-(1, the 1-dimethyl-4-piperidine) phosphate, 1-O-six decyls-2-O-methyl-rac-glyceryl-3-phosphocholine, 1-O-octadecyl-2-O-methyl-rac-glyceryl-3-phosphocholine, 1-O-octadecyl-2-O-methyl-sn-glyceryl-3-phosphocholine, inositolpolyphosphates, cyclosporin A, the basic phosphocholine of 14 (alkane), six certain herbaceous plants with big flowers base phosphoric acid (N-N-N-trimethyl) hexanol amine, D 19391, octadecyl-[2-(N-methyl piperidine) ethyl]-phosphate, aminotriazole(ATA) (AT) and DL-Buthionine-(S,R)-sulfoximine BSO are preferred.
When the cancer therapy drug in the medicament slow-release microsphere only was antitumor antibiotic or its synergist, the application of slow-releasing anticarcinogen injection and potentiation mode were:
(1) contain the slow releasing injection local injection of antitumor antibiotic, other approach of antitumor antibiotic synergist are used;
(2) local injection contains the slow releasing injection of antitumor antibiotic synergist, and other approach are used antitumor antibiotic;
(3) local injection contains the slow releasing injection and the slow releasing injection that contains the antitumor antibiotic synergist of antitumor antibiotic; Or
(4) local injection contains the slow releasing injection of antitumor antibiotic and synergist.
The slow-releasing anticarcinogen injection of topical application also is used for the potentiation to radiotherapy or other therapies.Other approach refer to, but, be not limited to tremulous pulse, vein, abdominal cavity, subcutaneous, intracavitary administration.
Antitumor antibiotic synergist and the percentage by weight of its synergist in medicament slow-release microsphere are 0.5%-60%, are good with 2%-40%, are best with 5%-30%.The weight ratio of antitumor antibiotic and antitumor antibiotic synergist is 1-9: 1 to 1: 1-9.With 1-2: 1 serves as preferred.
Anticancer effective component in the slow-releasing anticarcinogen injection microsphere of the present invention is preferably as follows, and all is weight percentage:
(a) bleomycin of 2-30%, amycin, epirubicin, ametycin, actinomycin D, aclarubicin, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star;
(b) the O4-benzyl folic acid, 2 of 2-40%, 4,5-triamido-6-benzyloxy pyrimidine, 2,4-diaminourea-6-benzyloxy-5-nitroso-group pyrimidine, 2,4-diaminourea-6-benzyloxy-5-bromo pyrimidine, 2-amino-4-benzyloxy-5-nitro-pyrimidine, 2-amino-4-benzyloxy-6-methyl-5-nitro pyrimidine, 2,4-diaminourea-6-benzyloxy-s-triazine or 2-amino-O4-benzyl pteridine;
(c) bleomycin of 2-30%, amycin, epirubicin, ametycin, actinomycin D, aclarubicin, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, the O4-benzyl folic acid of teloxantrone or chlorine assistant and 2-40%, 2,4,5-triamido-6-benzyloxy pyrimidine, 2,4-diaminourea-6-benzyloxy-5-nitroso-group pyrimidine, 2,4-diaminourea-6-benzyloxy-5-bromo pyrimidine, 2-amino-4-benzyloxy-5-nitro-pyrimidine, 2-amino-4-benzyloxy-6-methyl-5-nitro pyrimidine, 2, the combination of 4-diaminourea-6-benzyloxy-s-triazine or 2-amino-O4-benzyl pteridine;
(d) 7-hydroxy-star shaped spore native of 2-40%, 7-O-alkyl-star shaped spore native, beta-methoxy-star shaped spore native, alkyl phosphate choline or hexa-decyl choline phosphate;
(e) combination of 7-hydroxy-star shaped spore native, 7-O-alkyl-star shaped spore native, beta-methoxy-star shaped spore native, alkyl phosphate choline or the hexa-decyl choline phosphate of the bleomycin of 2-30%, amycin, epirubicin, ametycin, actinomycin D, aclarubicin, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant and 2-40%;
(f) imidazopyrazine of 2-40%, imidazopyridine, wortmannin, .alpha.-5:6-benzopyran, 2-(morphol-4-yl)-.alpha.-5:6-benzopyran-4-base, 2-(4-Lin Ji)-8-phenylchromone, 1-(2-hydroxyl-4-morphol-4-base-phenyl)-ethano-), inhibitors of kinases, vanillin, 2-aminopurine, 7-ethyl-10-hydroxycamptothecine, phenylbutyric acid salt, methylamine, methoxamine, hydroxylamine, minocycline, the O-hydroxylamine, O-methyl hydroxylamine or O-δ-ammonia oxygen-butyl hydroxylamine;
(g) bleomycin of 2-30%, amycin, epirubicin, ametycin, actinomycin D, aclarubicin, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, the imidazopyrazine of teloxantrone or chlorine assistant and 2-40%, imidazopyridine, wortmannin, .alpha.-5:6-benzopyran, 2-(morphol-4-yl)-.alpha.-5:6-benzopyran-4-base, 2-(4-Lin Ji)-8-phenylchromone, 1-(2-hydroxyl-4-morphol-4-base-phenyl)-ethano-), inhibitors of kinases, vanillin, 2-aminopurine, 7-ethyl-10-hydroxycamptothecine, phenylbutyric acid salt, methylamine, methoxamine, hydroxylamine, minocycline, the O-hydroxylamine, the combination of O-methyl hydroxylamine or O-δ-ammonia oxygen-butyl hydroxylamine; Or
(h) bleomycin of 2-40%, amycin, epirubicin, ametycin, actinomycin D, aclarubicin, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, the 3-aminobenzamide of teloxantrone or chlorine assistant and 2-40%, Benzoylamide, 3,4-dihydro methoxy isoquinolin-1 (2H)-Benzoylamide, AG14361, the poly polymerase inhibitor, the amino 2-aromatic radical benzimidazole-4-carboxamides BZ1-6 that replaces, benzimidazole-4-carboxamides BZ1-6, tricyclic lactam hydrogen sulfide, three ring benzimidazole carboxylic acid amides, benzimidazole, 1H-three ring benzimidazole carboxylic acid amides, 2-aromatic radical-1H-benzimidazole-4-carboxamides BZ1-6,2-phenyl-1H-benzimidazole-4-carboxamides BZ1-6,2-(4-hydroxymethyl phenyl)-1H-benzimidazole-4-carboxamides BZ1-6,2-(3-anisyl)-1H-benzimidazole-4-carboxamides BZ1-6, the combination of 8-hydroxy-2-methyl quinazolinone or 2-(4-hydroxyphenyl) benzimidazole-4-carboxamides BZ1-6; Or
(i) 2-40% aminotriazole(ATA), DL-Buthionine-(S,R)-sulfoximine BSO, cavatic acid, S-hexyl glutathion, new podophyllotoxin, Exatecan mesylate or TAN-1518; Or
(j) combination of the aminotriazole(ATA) of the bleomycin of 2-30%, amycin, epirubicin, ametycin, actinomycin D, aclarubicin, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant and 2-40%, DL-Buthionine-(S,R)-sulfoximine BSO, cavatic acid, S-hexyl glutathion, new podophyllotoxin, Exatecan mesylate or TAN-1518.
One of the copolymer (PLGA) of the preferred polylactic acid of slow-release auxiliary material (PLA), polyglycolic acid and hydroxyacetic acid, ethylene vinyl acetate copolymer (EVAc), polifeprosan, bis-fatty acid and decanedioic acid copolymer, poly-(erucic acid dimer-decanedioic acid) copolymer, poly-(fumaric acid-decanedioic acid) copolymer or its combination.
When selecting the copolymer (PLGA) of polylactic acid (PLA), polyglycolic acid (PGA), polylactic acid (PLA) and mixture, glycolic and the hydroxy carboxylic acid of polyglycolic acid for use, PLA and PLGA content percentage by weight are respectively 0.1-99.9% and 99.9-0.1%.The molecular weight peak value of polylactic acid can be, but is not limited to, 5000-100, and 000, but with 20,000-60,000 is preferred, with 30,000-50,000 for most preferably; The molecular weight of polyglycolic acid can be, but is not limited to, 5000-100, and 000, but with 20,000-60,000 is preferred, with 30,000-50,000 for most preferably; Above polyhydroxy acid can singly select or multiselect.When singly selecting, serve as preferred with the copolymer (PLGA) of polylactic acid (PLA) or hydroxy carboxylic acid and glycolic, the molecular weight of copolymer can be, but is not limited to, 5000-100,000, but with 20,000-60,000 be preferably, with 30,000-50,000 for most preferably; When multiselect, compound polymer or the copolymer formed with macromolecule polymer or different macromolecule polymer serve as preferred, with the compound polymer that contains different molecular weight polylactic acid or decanedioic acid or copolymer for most preferably, as, but be not limited to, molecular weight is 1000 to 30000 polylactic acid with molecular weight is that 20000 to 50000 polylactic acid mixes, molecular weight is 10000 to 30000 polylactic acid with molecular weight is that 30000 to 80000 PLGA mixes, molecular weight is that 20000 to 30000 polylactic acid mixes with decanedioic acid, molecular weight is that 30000 to 80000 PLGA mixes with decanedioic acid.
In various high molecular polymers, with polylactic acid, decanedioic acid, the mixture or the copolymer that contain the macromolecule polymer of polylactic acid or certain herbaceous plants with big flowers diacid is first-selection, mixture and copolymer can be selected from, but be not limited to the mixture or the copolymer of the mixture of PLA, PLGA, glycolic and hydroxy carboxylic acid, certain herbaceous plants with big flowers diacid and fragrant polyanhydride or aliphatic polyanhydride.The blend ratio of glycolic and hydroxy carboxylic acid is 10/90-90/10 (weight), preferably 25/75-75/25 (weight).The method of blend is arbitrarily.Content when glycolic and hydroxy carboxylic acid copolymerization is respectively percentage by weight 10-90% and 90-10%.The representative of fragrance polyanhydride is polifeprosan [poly-(1,3-two (to the carboxyl phenoxy group) propane-decanedioic acid) (p (CPP-SA)), bis-fatty acid-decanedioic acid copolymer (PFAD-SA)], poly-(erucic acid dimer-decanedioic acid) [P (EAD-SA)] and poly-(fumaric acid-decanedioic acid) [P (FA-SA)] etc.Content during to carboxylic phenoxypropane (p-CPP) and decanedioic acid copolymerization is respectively percentage by weight 10-60% and 20-90%, and the blend weight ratio is 10-40: 50-90, preferably weight ratio 15-30: 65-85.
Except that above-mentioned adjuvant, also can select for use other materials to see the United States Patent (USP) (patent No. 4757128; 4857311; 4888176; 4789724) and in " pharmaceutic adjuvant complete works " (the 123rd page, Sichuan science tech publishing house published in 1993, Luo Mingsheng and Gao Tianhui chief editor) have a detailed description.In addition, Chinese patent (application number 96115937.5; 91109723.6; 9710703.3; 01803562.0) and U.S.'s patent of invention (patent No. 5,651,986) also enumerated some pharmaceutic adjuvant, comprise filler, solubilizing agent, absorption enhancer, film former, gellant, system (or causing) hole agent, excipient or blocker etc.
For regulating drug releasing rate or changing other characteristic of the present invention, can change the composition and the proportioning of monomer component or molecular weight, interpolation or the adjusting pharmaceutic adjuvant of polymer, add the water-soluble low-molecular chemical compound, as, but be not limited to various sugar or salt etc.Wherein sugar can be, but is not limited to, xylitol, oligosaccharide, (sulphuric acid) chrondroitin and chitin etc., and wherein salt can be, but is not limited to, potassium salt and sodium salt etc.
In the slow releasing injection, drug sustained release system can be made into microsphere, sub-micro ball, microemulsion, nanosphere, granule or spherical piller, makes the injection use then with after the injection solvent mixes.In various slow releasing injection, serve as preferred with the suspension type slow releasing injection, the suspension type slow releasing injection is the preparation that the drug sustained release system that will contain anticancer component is suspended in gained in the injection, used adjuvant is a kind of or its combination in the above-mentioned slow-release auxiliary material, and used solvent is common solvent or the special solvent that contains suspending agent.Common solvent is, but is not limited to the buffer that distilled water, water for injection, physiology are prepared towards liquid, dehydrated alcohol or various salt.The purpose of suspending agent is the pastille microsphere that effectively suspends, thereby is beneficial to the usefulness of injection.
Suspending agent is selected from one of sodium carboxymethyl cellulose, (iodine) glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40 and soil temperature 80 or its combination.
The content of suspending agent in common solvent is decided because of its characteristic, can be 0.1-30% and decides because of concrete condition.Consisting of of preferred suspending agent:
A) 0.5-5% sodium carboxymethyl cellulose+0.1-0.5% soil temperature 80; Or
B) 5-20% mannitol+0.1-0.5% soil temperature 80; Or.
C) 0.5-5% sodium carboxymethyl cellulose+5-20% sorbitol+0.1-0.5% soil temperature 80.
The kind of solvent is then depended in the preparation of solvent, and common solvent has commercially available, also can make by oneself, and as distilled water, water for injection, physiology buffer towards liquid, dehydrated alcohol or the preparation of various salt, but must be in strict accordance with related standards.Special solvent need be considered the kind of suspending agent and the medicine that composition, solvent suspended, composition, character and the requirement thereof of sustained-release micro-spheres (or microcapsule) and the preparation method of injection, as sodium carboxymethyl cellulose (1.5%)+mannitol and/or sorbitol (15%) and/or soil temperature 80 (0.1%) are dissolved in the normal saline mutually deserved solvent, viscosity is at 10cp-650cp (20 ℃-30 ℃ time).
The present invention finds to influence medicine and/or sustained-release micro-spheres suspends and/or the key factor of injection is the viscosity of solvent, and viscosity is big more, and suspension effect is good more, and syringeability is strong more.This unexpected one of main index characteristic of the present invention of finding to have constituted.The viscosity of solvent depends on the viscosity of suspending agent, and the viscosity of suspending agent is 100cp-3000cp (20 ℃-30 ℃ time), preferred 1000cp-3000cp (20 ℃-30 ℃ time), most preferably 1500cp-3000cp (20 ℃-30 ℃ time).According to the viscosity of the prepared solvent of this condition is 10cp-650cp (20 ℃-30 ℃ time), preferred 20cp-650cp (20 ℃-30 ℃ time), most preferably 60cp-650cp (20 ℃-30 ℃ time).
The preparation of injection has several different methods, and a kind of is that the sustained-release microparticle (A) of suspending agent for " 0 " directly mixed in special solvent, obtains corresponding sustained-release microparticle injection; Another kind is that suspending agent is not mixed in special solvent or common solvent for the sustained-release microparticle (A) of " 0 ", obtains corresponding sustained-release microparticle injection; Another is that sustained-release microparticle (A) is mixed in common solvent, adds the suspending agent mixing then, obtains corresponding sustained-release microparticle injection.Except, also can earlier sustained-release microparticle (A) be mixed and in special solvent, make corresponding suspension, with the moisture in ways such as the vacuum drying removal suspension, special solvent of reuse or common solvent suspendible obtain corresponding sustained-release microparticle injection afterwards then.Above method just is illustrative rather than definitive thereof the present invention.It should be noted that suspended drug or sustained-release micro-spheres (or microcapsule) concentration in injection decide because of specifically needing, can be, but be not limited to, 10-400mg/ml, but be preferably with 30-300mg/ml, with 50-200mg/ml most preferably.The viscosity of injection is 50cp-1000cp (20 ℃-30 ℃ time), preferred 100cp-1000cp (20 ℃-30 ℃ time), most preferably 200cp-650cp (20 ℃-30 ℃ time).So viscosity is applicable to 18-22 injection needle and special bigger (to 3 millimeters) injection needle of internal diameter.
The preparation method of slow releasing injection is arbitrarily, available some kinds of methods preparation: as, but be not limited to, mixing method, fusion method, dissolution method, spray drying method for preparation microsphere, dissolution method are made micropowder, liposome bag medicine method and emulsion process etc. in conjunction with freezing (drying) comminuting method.Serve as preferred wherein with dissolution method (being the solvent volatility process), seasoning, spray drying method and emulsion process.Microsphere then can be used for preparing above-mentioned various slow releasing injection, and its method is arbitrarily.The particle size range of used microsphere can be between 5-400um, serving as preferred between the 10-300um, with between the 20-200um for most preferably.
Microsphere also can be used for preparing other slow releasing injection, as gel injection, block copolymer micelle injection.Wherein, block copolymer micelle is formed in aqueous solution by hydrophobic-hydrophilic block copolymers, has spherical inner core-shell mechanism, and hydrophobic block forms kernel, and hydrophilic block forms shell.The carrier micelle injection enters the purpose that reaches control drug release or targeted therapy in the body.Used pharmaceutical carrier is above-mentioned any one or its combination.Wherein preferred molecular weight is the hydrophilic block of the Polyethylene Glycol (PEG) of 1000-15000 as the micelle copolymer, and preferred biological degradation polyalcohol (as PLA, polylactide, polycaprolactone and copolymer thereof (molecular weight 1500-25000)) is as the hydrophobic block of micelle copolymer.The particle size range of block copolymer micelle can be between 10-300um, between the 20-200um serving as preferred.Gel injection system is dissolved in some amphipathic solvent with biological degradation polyalcohol (as PLA, PLGA or DL-LA and epsilon-caprolactone copolymer), adds medicine miscible with it (or suspendible) back again and forms flowability gel preferably, can be through tumor week or intratumor injection.In case inject, amphipathic solvent diffuses to body fluid very soon, the moisture in the body fluid then infiltrates gel, makes polymer cure, slowly discharges medicine.
Sustained-release micro-spheres also can be used for preparing sustained-release implant, used pharmaceutic adjuvant can be any or multiple material in the above-mentioned pharmaceutic adjuvant, but with the high molecular weight water soluble polymer is main separation, in various high molecular polymers, with polylactic acid, certain herbaceous plants with big flowers diacid, the mixture or the copolymer that contain the macromolecule polymer of polylactic acid or certain herbaceous plants with big flowers diacid is first-selection, mixture and copolymer can be selected from, but be not limited to the mixture or the copolymer of the mixture of PLA, PLGA, PLA and PLGA, certain herbaceous plants with big flowers diacid and fragrant polyanhydride or aliphatic polyanhydride.Polylactic acid (PLA) and polyglycolic acid the blend ratio be 10/90-90/10 (weight), 25/75-75/25 (weight) preferably.The method of blend is arbitrarily.Content when glycolic and lactic acid copolymerization is respectively percentage by weight 10-90% and 90-10%.The representative of fragrance polyanhydride is to carboxy phenyl propane (p-CPP), content during to carboxy phenyl propane (p-CPP) and the copolymerization of certain herbaceous plants with big flowers diacid is respectively percentage by weight 10-60% and 20-90%, the blend weight ratio is 10-40: 50-90, preferably weight ratio 15-30: 65-85.
Another form of anticancer medicine slow-release preparation containing of the present invention is that anticancer medicine slow-release preparation containing is a sustained-release implant.The effective ingredient of anticancer implant can be packaged in the whole pharmaceutic adjuvant equably, also can be packaged in carrier holder center or its surface; Can effective ingredient be discharged by direct diffusion and/or the mode of degrading through polymer.
The characteristics of sustained-release implant are that used slow-release auxiliary material removes the high molecular polymerization beyond the region of objective existence, also contain above-mentioned any one or multiple other adjuvant.The pharmaceutic adjuvant that adds is referred to as additive.Additive can be divided into filler, porogen, excipient, dispersant, isotonic agent, preservative agent, blocker, solubilizing agent, absorption enhancer, film former, gellant etc. according to its function.
The Main Ingredients and Appearance of sustained-release implant can be made into multiple dosage form.As, but be not limited to capsule, slow releasing agent, implant, slow releasing agent implant etc.; Be multiple shape, as, but be not limited to pill, tablet, powder, granule, sphere, bulk, needle-like, bar-shaped, column and membranaceous.In various dosage forms, serve as preferred slowly to discharge implant in the body.
The most preferred dosage form of sustained-release implant is that the slow releasing agent that biocompatibility, degradable absorb is implanted, and can make different shape and various dosage form because of the clinical needs of difference.The packing method of its Main Ingredients and Appearance and step in United States Patent (USP) (US5651986) have a detailed description, comprise the some kinds of methods that prepare slow releasing preparation: as, but be not limited to, (i) carrier holder powder and medicament mixed be pressed into implant then, promptly so-called mixing method; (ii) carrier holder fusing, mix solid cooled then, promptly so-called fusion method mutually with medicine to be packaged; (iii) the carrier holder is dissolved in the solvent, medicine dissolution to be packaged or be scattered in the polymer solution, evaporating solvent then, drying, promptly so-called dissolution method; (iv) spray drying method; And (v) freeze-drying etc.
Anticancer effective component and percentage by weight in the sustained-release implant are preferably as follows:
(a) aclarubicin of 2-30%, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star;
(b) the O4-benzyl folic acid, 2 of 2-40%, 4,5-triamido-6-benzyloxy pyrimidine, 2,4-diaminourea-6-benzyloxy-5-nitroso-group pyrimidine, 2,4-diaminourea-6-benzyloxy-5-bromo pyrimidine, 2-amino-4-benzyloxy-5-nitro-pyrimidine, 2-amino-4-benzyloxy-6-methyl-5-nitro pyrimidine, 2,4-diaminourea-6-benzyloxy-s-triazine or 2-amino-O4-benzyl pteridine;
(c) aclarubicin of 2-30%, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, the O4-benzyl folic acid of teloxantrone or chlorine assistant star and 2-40%, 2,4,5-triamido-6-benzyloxy pyrimidine, 2,4-diaminourea-6-benzyloxy-5-nitroso-group pyrimidine, 2,4-diaminourea-6-benzyloxy-5-bromo pyrimidine, 2-amino-4-benzyloxy-5-nitro-pyrimidine, 2-amino-4-benzyloxy-6-methyl-5-nitro pyrimidine, 2, the combination of 4-diaminourea-6-benzyloxy-s-triazine or 2-amino-O4-benzyl pteridine;
(d) 7-hydroxy-star shaped spore native of 2-40%, 7-O-alkyl-star shaped spore native, beta-methoxy-star shaped spore native, alkyl phosphate choline or hexa-decyl choline phosphate;
(e) combination of 7-hydroxy-star shaped spore native, 7-O-alkyl-star shaped spore native, beta-methoxy-star shaped spore native, alkyl phosphate choline or the hexa-decyl choline phosphate of the aclarubicin of 2-30%, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star and 2-40%;
(f) imidazopyrazine of 2-40%, imidazopyridine, wortmannin, .alpha.-5:6-benzopyran, 2-(morphol-4-yl)-.alpha.-5:6-benzopyran-4-base, 2-(4-Lin Ji)-8-phenylchromone, 1-(2-hydroxyl-4-morphol-4-base-phenyl)-ethano-), inhibitors of kinases, vanillin, 2-aminopurine, 7-ethyl-10-hydroxycamptothecine, phenylbutyric acid salt, methylamine, methoxamine, hydroxylamine, minocycline, the O-hydroxylamine, O-methyl hydroxylamine or O-δ-ammonia oxygen-butyl hydroxylamine;
(g) aclarubicin of 2-30%, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, the imidazopyrazine of teloxantrone or chlorine assistant star and 2-40%, imidazopyridine, wortmannin, .alpha.-5:6-benzopyran, 2-(morphol-4-yl)-.alpha.-5:6-benzopyran-4-base, 2-(4-Lin Ji)-8-phenylchromone, 1-(2-hydroxyl-4-morphol-4-base-phenyl)-ethano-), inhibitors of kinases, vanillin, 2-aminopurine, 7-ethyl-10-hydroxycamptothecine, phenylbutyric acid salt, methylamine, methoxamine, hydroxylamine, minocycline, the O-hydroxylamine, the combination of O-methyl hydroxylamine or O-δ-ammonia oxygen-butyl hydroxylamine; Or
(h) aclarubicin of 2-40%, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, the 3-aminobenzamide of teloxantrone or chlorine assistant star and 2-40%, Benzoylamide, 3,4-dihydro methoxy isoquinolin-1 (2H)-Benzoylamide, AG14361, the poly polymerase inhibitor, the amino 2-aromatic radical benzimidazole-4-carboxamides BZ1-6 that replaces, benzimidazole-4-carboxamides BZ1-6, tricyclic lactam hydrogen sulfide, three ring benzimidazole carboxylic acid amides, benzimidazole, 1H-three ring benzimidazole carboxylic acid amides, 2-aromatic radical-1H-benzimidazole-4-carboxamides BZ1-6,2-phenyl-1H-benzimidazole-4-carboxamides BZ1-6,2-(4-hydroxymethyl phenyl)-1H-benzimidazole-4-carboxamides BZ1-6,2-(3-anisyl)-1H-benzimidazole-4-carboxamides BZ1-6, the combination of 8-hydroxy-2-methyl quinazolinone or 2-(4-hydroxyphenyl) benzimidazole-4-carboxamides BZ1-6; Or
(i) 2-40% aminotriazole(ATA), DL-Buthionine-(S,R)-sulfoximine BSO, cavatic acid, S-hexyl glutathion, new podophyllotoxin, Exatecan mesylate or TAN-1518; Or
(j) combination of the aminotriazole(ATA) of the aclarubicin of 2-30%, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star and 2-40%, DL-Buthionine-(S,R)-sulfoximine BSO, cavatic acid, S-hexyl glutathion, new podophyllotoxin, Exatecan mesylate or TAN-1518.
When the cancer therapy drug in the medicament slow-release microsphere only is antitumor antibiotic or its synergist, the application of anti-cancer sustained-released implantation agent and the same slow releasing injection of potentiation mode.
Route of administration depends on multiple factor, for obtain valid density in former or position, metastatic tumour place, medicine can give through number of ways, as in subcutaneous, intracavity (in abdominal cavity, thoracic cavity and canalis spinalis), the tumor, in all injections of tumor or placement, selective arterial injection, the lymph node and injection in the bone marrow.With in selective arterial injection, intracavity, the tumor, tumor week injection or be placed as preferred.
The present invention can be used to prepare the pharmaceutical preparation of the various tumors for the treatment of people and animal, be mainly slow releasing injection or sustained-release implant, the indication tumor comprises former or cancer or sarcoma or the carcinosarcoma that shifts that originates from brain, central nervous system, kidney, liver, gallbladder, incidence, oral cavity, thyroid, skin, mucosa, body of gland, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, uterus, ovary, endometrium, cervix uteri, prostate, bladder, colon, rectum.
Also can add other medicinal ingredient in slow releasing injection that the present invention is made or the sustained-release implant, as, but be not limited to antibiotics, antalgica, anticoagulant medicine, hemorrhage etc.
By following test and embodiment technical method of the present invention is further described:
The local drug concentration that test 1, different modes are used behind the antitumor antibiotic (valrubicin) compares
With the rat is subjects, with 2 * 10 5Individual prostate tumor cells subcutaneous injection is in its hypochondrium, treats behind tumor growth to 1 cm diameter its grouping.Every group of dosage is the 5mg/kg valrubicin.Measure medicament contg (%) in the different time tumor, the result shows, the local drug concentration significant difference of valrubicin after different modes is used, topical can obviously improve and effectively keep the active drug concentration at position, tumor place, and is wherein best with the effect of placing sustained-release implant and intratumor injection slow releasing injection in the tumor.Yet, intratumor injection slow releasing injection operation most convenient, easy.This discovery constitutes key character of the present invention.Following relevant inhibition test has further confirmed this point.
The interior tumor-inhibiting action of body that test 2, different modes are used behind the antitumor antibiotic (pirarubicin) compares
With the rat is subjects, with 2 * 10 5Individual prostate tumor cells subcutaneous injection is in its hypochondrium, treats behind tumor growth to 0.5 cm diameter its grouping.Every group of dosage is the 5mg/kg pirarubicin.The treatment back was measured gross tumor volume size, relatively therapeutic effect on the 10th day.The result shows, the tumor-inhibiting action significant difference of pirarubicin after different modes is used, topical can obviously improve and effectively keep the active drug concentration at position, tumor place, and is wherein best with the effect of placing sustained-release implant and intratumor injection slow releasing injection in the tumor.Yet, intratumor injection slow releasing injection operation most convenient, easy.Good effect not only, toxic and side effects is also little.
Test 3, contain tumor-inhibiting action in the body of antitumor antibiotic and antitumor antibiotic synergist (slow releasing injection)
With the rat is subjects, with 2 * 10 5Individual pancreatic tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 1).First group is contrast, and the 2nd to 10 group is the treatment group, and medicine is all through intratumor injection.Dosage is 5mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 1) on the 10th day.
Table 1
Test group (n) Suffered treatment Gross tumor volume (cm 3) The P value
1(6) Contrast 68±10
2(6) Antitumor antibiotic 52±5.0 ＜0.05
3(6) UCN-01 52±2.0 ＜0.01
4(6) UCN-02 48±2.2 ＜0.01
5(6) MIL 58±5.2 ＜0.01
6(6) D-21266 40±3.0 ＜0.01
7(6) Antitumor antibiotic+UCN-01 22±2.2 ＜0.001
8(6) Antitumor antibiotic+UCN-02 30±3.8 ＜0.001
9(6) Antitumor antibiotic+MIL 32±3.6 ＜0.001
10(6) Antitumor antibiotic+D-21266 18±2.0 ＜0.001
Above result shows, antitumor antibiotic (pirarubicin) and used antitumor antibiotic synergist-phosphoinositide 3-kinase (PI3K) inhibitor (UCN-01:7-hydroxy-star shaped spore native wherein; UCN-02:7-O-alkyl-star shaped spore native; MIL:Miltefosine or hexa-decyl choline phosphate; D-21266: octadecyl-(1, the 1-dimethyl-4-piperidine) phosphate or perifosine) growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately, can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 4, antitumor antibiotic and antitumor antibiotic synergist (slow releasing injection)
Used tumor cell comprises CNS-1, C6,9L, gastric gland epithelial cancer (SA), bone tumor (BC), breast carcinoma (BA), pulmonary carcinoma (LH), papillary adenocarcinoma of thyroid (PAT), hepatocarcinoma etc.Antitumor antibiotic and antitumor antibiotic synergist are added in 24 hours the various tumor cells of In vitro culture by 10ug/ml concentration, continue to cultivate counting cells sum after 48 hours.Its growth of tumour cell suppresses effect and is shown in Table 2.
Table 2
Oncocyte Antitumor antibiotic O4-BA UCN-01 UCN-02 Antitumor antibiotic+O4-BA Antitumor antibiotic+UCN-1 Antitumor antibiotic+UCN-2
CNS 60％ 58％ 64％ 68％ 90％ 82％ 84％
C6 64％ 64％ 60％ 64％ 94％ 80％ 94％
SA 54％ 62％ 56％ 62％ 86％ 92％ 92％
BC 54％ 64％ 54％ 64％ 94％ 82％ 82％
BA 58％ 60％ 62％ 60％ 92％ 92％ 92％
LH 62％ 58％ 62％ 58％ 90％ 86％ 84％
PAT 64％ 54％ 62％ 58％ 94％ 84％ 82％
Above result shows, used antitumor antibiotic (valrubicin) and antitumor antibiotic synergist (O4-BA:O4-benzyl uric acid; UCN-01:7-hydroxy-star shaped spore native; UCN-02:7-O-alkyl-star shaped spore native) growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately, can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 5, antitumor antibiotic and antitumor antibiotic synergist (slow releasing injection)
With the rat is subjects, with 2 * 10 5Individual tumor cell of liver subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 3).First group is contrast, and the 2nd to 10 group is the treatment group, and sustained-release implant is placed in tumor.Dosage is 5mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 3) on the 10th day.
Table 3
Test group (n) Suffered treatment Gross tumor volume (cm 3) The P value
1(6) Contrast 80±10
2(6) ilmofosine 48±5.3 ＜0.05
3(6) Antitumor antibiotic 52±2.3 ＜0.01
4(6) The ilmofosine+ antitumor antibiotic 30±2.6 ＜0.001
5(6) AMG-PC 48±3.0 ＜0.01
6(6) The AMG-PC+ antitumor antibiotic 26±3.0 ＜0.001
7(6) edelfosine 30±2.8 ＜0.01
8(6) The Edelfosine+ antitumor antibiotic 20±2.6 ＜0.001
9(6) IDOU 30±3.2 ＜0.01
10(6) The IDOU+ antitumor antibiotic 18±2.0 ＜0.001
Above result shows, used antitumor antibiotic (darubicin) and antitumor antibiotic synergist-PI3K inhibitor (wherein, AMG-PC:1-O-six decyls-2-O-methyl-rac-glyceryl-3-phosphocholine; Edelfosine:1-O-octadecyl-2-O-methyl-rac-glyceryl-3-phosphocholine; Ilmofosine:1-O-octadecyl-2-O-methyl-sn-glyceryl-3-phosphocholine; IDOU:5-iodo-2 '-deoxyguanosine) growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately, can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 6, antitumor antibiotic and antitumor antibiotic synergist (slow releasing injection)
With the rat is subjects, with 2 * 10 5Individual prostate tumor cells subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it negative control (blank), single therapy group (antitumor antibiotic or antitumor antibiotic synergist) and therapeutic alliance group (antitumor antibiotic and antitumor antibiotic synergist).Antitumor antibiotic is through intratumor injection, and the antitumor antibiotic synergist is through lumbar injection.Dosage is 5mg/kg.The treatment back was measured the gross tumor volume size on the 10th day, made relatively therapeutic effect (seeing Table 4) of index with inhibition rate of tumor growth.
Table 4
Test group (n) Suffered treatment Tumor control rate (%) The P value
1(6) Contrast -
2(6) Antitumor antibiotic 62 ＜0.05
3(6) Imidazopyrazine 26 ＜0.01
Test group (n) Suffered treatment Tumor control rate (%) The P value
4(6) Imidazopyridine 28 ＜0.01
5(6) Wortmannin 24 ＜0.01
6(6) .alpha.-5:6-benzopyran 32 ＜0.01
7(6) Antitumor antibiotic+imidazopyrazine 84 ＜0.001
8(6) Antitumor antibiotic+imidazopyridine 88 ＜0.001
9(6) Antitumor antibiotic+wortmannin 88 ＜0.001
10(6) Antitumor antibiotic+.alpha.-5:6-benzopyran 90 ＜0.001
Above result shows, the kinases inhibitor that used antitumor antibiotic (pirarubicin) and antitumor antibiotic synergist-DNA-relies on (wherein, imidazopyrazine, imidazopyridine, wortmannin .alpha.-5:6-benzopyran) growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately, can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 7, antitumor antibiotic and antitumor antibiotic synergist (slow releasing injection)
With the rat is subjects, with 2 * 10 5Individual breast tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it negative control (blank), single therapy group, therapeutic alliance group.Antitumor antibiotic is through lumbar injection, and the antitumor antibiotic synergist is through the injection of tumor week.Dosage is 5mg/kg.The treatment back was measured the gross tumor volume size on the 10th day, made relatively therapeutic effect (seeing Table 5) of index with inhibition rate of tumor growth.
Table 5
Test group (n) Suffered treatment Tumor control rate (%) The P value
1(6) Contrast -
2(6) Antitumor antibiotic 26 ＜0.05
3(6) LY294002 70 ＜0.01
4(6) SU11752 66 ＜0.01
5(6) SN-38 74 ＜0.01
6(6) OK-1035 66 ＜0.01
7(6) Antitumor antibiotic+LY294002 90 ＜0.001
Test group (n) Suffered treatment Tumor control rate (%) The P value
8(6) Antitumor antibiotic+SU11752 86 ＜0.001
9(6) Antitumor antibiotic+SN-38 88 ＜0.001
10(6) Antitumor antibiotic+OK-1035 82 ＜0.001
Above result shows, kinases inhibitor (wherein, LY294002:2-(4-Lin Ji)-8-phenylchromone that used antitumor antibiotic (aclarubicin) and antitumor antibiotic synergist-DNA-relies on; SU11752: inhibitors of kinases; SN-38:7-ethyl-10-hydroxycamptothecine; Growth all has the obvious suppression effect to OK-1035:3-cyano group-6-hydrazono-methyl-5-(4-pyridine radicals) pyridine-[1H]-2-1) to kinds of tumor cells when this concentration is used separately, can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 8, antitumor antibiotic and antitumor antibiotic synergist (sustained-release implant)
With the rat is subjects, with 2 * 10 5Individual breast tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it negative control (blank), single therapy group, therapeutic alliance group.Sustained-release implant is all placed in tumor.Dosage is 5mg/kg.The treatment back was measured the gross tumor volume size on the 10th day, made relatively therapeutic effect (seeing Table 6) of index with inhibition rate of tumor growth.
Table 6
Test group (n) Suffered treatment Tumor control rate (%) The P value
1(6) Contrast -
2(6) Antitumor antibiotic 58 ＜0.05
3(6) Methoxamine 50 ＜0.05
4(6) Minocycline 48 ＜0.05
5(6) Hydroxylamine 38 ＜0.05
6(6) O-methyl hydroxylamine 32 ＜0.01
7(6) Antitumor antibiotic+methoxamine 80 ＜0.01
8(6) Antitumor antibiotic+minocycline 76 ＜0.01
9(6) Antitumor antibiotic+hydroxylamine 88 ＜0.01
10(6) Antitumor antibiotic+O-methyl hydroxylamine 86 ＜0.001
Above result shows, growth all has the obvious suppression effect to the kinases inhibitor that used antitumor antibiotic (mitoxantrone) and antitumor antibiotic synergist-DNA-relies on to kinds of tumor cells when this concentration is used separately, can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 9, antitumor antibiotic and antitumor antibiotic synergist (sustained-release implant)
By the tumor-inhibiting action of test 8 described methods mensuration antitumor antibiotics and antitumor antibiotic synergist (sustained-release implant), its inhibition rate of tumor growth sees Table 7.
Table 7
Test group (n) Suffered treatment Tumor control rate (%) The P value
1(6) Contrast -
2(6) Antitumor antibiotic 52 ＜0.05
3(6) 3-AB 46 ＜0.01
4(6) Benzoylamide 46 ＜0.01
5(6) PD128763 42 ＜0.01
6(6) AG14361 38 ＜0.01
7(6) Antitumor antibiotic+3-AB 88 ＜0.001
8(6) Antitumor antibiotic+Benzoylamide 78 ＜0.001
9(6) Antitumor antibiotic+PD128763 94 ＜0.001
10(6) Antitumor antibiotic+AG14361 86 ＜0.001
Above result shows, used antitumor antibiotic (clarithromycin) and antitumor antibiotic synergist-poly-(ADP-ribose) AG14361 (wherein, 3-AB:3-aminobenzamide; Benzoylamide; PD 128763:3,4-dihydro methoxy isoquinolin-1 (2H)-Benzoylamide; AG14361: AG14361) growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately, can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 10, antitumor antibiotic and antitumor antibiotic synergist (slow releasing injection)
By the tumor-inhibiting action of test 8 described methods mensuration antitumor antibiotics and antitumor antibiotic synergist (sustained-release implant), its inhibition rate of tumor growth sees Table 8.
Table 8
Test group (n) Suffered treatment Tumor control rate (%) The P value
1(6) Contrast -
2(6) Antitumor antibiotic 50 ＜0.05
Test group (n) Suffered treatment Tumor control rate (%) The P value
3(6) BZ1-6 50 ＜0.01
4(6) TI1-5 36 ＜0.01
5(6) TBC 42 ＜0.01
6(6) Benzimidazole 46 ＜0.01
7(6) Antitumor antibiotic+BZ16 78 ＜0.001
8(6) Antitumor antibiotic+TI1-5 88 ＜0.001
9(6) Antitumor antibiotic+TBC 78 ＜0.001
10(6) Antitumor antibiotic+benzimidazole 88 ＜0.001
Above result shows, used antitumor antibiotic (amycin) and antitumor antibiotic synergist-poly-(ADP-ribose) AG14361 (wherein, BZ1-6: benzimidazole-4-carboxamides BZ1-6; TI1-5: tricyclic lactam hydrogen sulfide; TBC: three ring benzimidazole carboxylic acid amides, benzimidazole) growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately, can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 11, antitumor antibiotic and/or antitumor antibiotic synergist (sustained-release implant)
By the tumor-inhibiting action of test 8 described methods mensuration antitumor antibiotics and/or antitumor antibiotic synergist (sustained-release implant), its inhibition rate of tumor growth sees Table 9.
Table 9
Test group (n) Suffered treatment Tumor control rate (%) The P value
1(6) Contrast -
2(6) Antitumor antibiotic 50 ＜0.05
3(6) NU1025 46 ＜0.01
4(6) PBC 32 ＜0.01
5(6) MPBC 46 ＜0.01
6(6) NU1085 42 ＜0.01
7(6) Antitumor antibiotic+NU1025 78 ＜0.001
Test group (n) Suffered treatment Tumor control rate (%) The P value
8(6) Antitumor antibiotic+PBC 86 ＜0.001
9(6) Antitumor antibiotic+MPBC 80 ＜0.001
10(6) Antitumor antibiotic+NU1085 94 ＜0.001
Above result shows, used antitumor antibiotic (ametycin) and antitumor antibiotic synergist-poly-(ADP-ribose) AG14361 (wherein, PBC:2-phenyl-1H-benzimidazole-4-carboxamides BZ1-6; MPBC:2-(3-anisyl)-1H-benzimidazole-4-carboxamides BZ1-6 (2-(3-methoxyphenyl)-1H-benzimidazole-4-carboxamide; NU1025:8-hydroxy-2-methyl quinazolinone; NU1085:2-(4-hydroxyphenyl) benzimidazole-4-carboxamides BZ1-6) growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately, can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 12, antitumor antibiotic and/or antitumor antibiotic synergist (sustained-release implant)
By the tumor-inhibiting action of test 6 described methods mensuration antitumor antibiotics and/or antitumor antibiotic synergist (sustained-release implant), its inhibition rate of tumor growth sees Table 10.
Table 10
Test group (n) Suffered treatment Tumor control rate (%) The P value
1(6) Contrast -
2(6) Antitumor antibiotic 60 ＜0.05
3(6) BSO 46 ＜0.01
4(6) Aminotriazole(ATA) 24 ＜0.01
5(6) Cavatic acid 40 ＜0.01
6(6) New podophyllotoxin 44 ＜0.01
7(6) Antitumor antibiotic+BSO 82 ＜0.001
8(6) Antitumor antibiotic+aminotriazole(ATA) 88 ＜0.001
9(6) Antitumor antibiotic+cavatic acid 76 ＜0.001
10(6) Antitumor antibiotic+new podophyllotoxin 82 ＜0.001
Above result shows, used antitumor antibiotic (epirubicin) and antitumor antibiotic synergist-poly-(ADP-ribose) AG14361 (wherein, BSO is a DL-Buthionine-(S,R)-sulfoximine BSO) growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately, can show significant potentiation when use in conjunction.
Further test shows bleomycin, daunomycin, amycin, triferricdoxorubicin, epirubicin, 7-O-methyl Nuo Jia-4 '-epirubicin, diethoxy acetyl amycin, ametycin, actinomycin D, nocardin, nocardorubin., 2-[N-(2-amidinoethyl)carbamoyl, nogalamycin, Mitochromine mitocromine B-35251, polymyxin E, pirlimycin, dirithromycin, antramycin, peplomycin, puromycin, sparsomycin, anthramycin, Carrninomycin I, puromycin, aclarubicin, aklavine-B, darubicin, Diacetoxysciroenol, clarithromycin, 9-[4-(N-Methylacetamido)anilino, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star can strengthen the action effect of poly-(ADP-ribose) AG14361 and other antitumor antibiotic synergist to some extent.
In a word, growth all had the obvious suppression effect to kinds of tumor cells when used antitumor antibiotic and various antitumor antibiotic synergist were used separately, can show significant potentiation when use in conjunction.Therefore, effective ingredient of the present invention is the combination of antitumor antibiotic and any one antitumor antibiotic synergist.The medicine that contains above effective ingredient can be made into sustained-release micro-spheres, and then makes slow releasing injection and implant, serves as preferred with the suspensoid injectio that is combined to form with the special solvent that contains suspending agent wherein.
Slow releasing injection or sustained-release implant also can be further specified by following embodiment.Just the invention will be further described for the foregoing description and following examples, is not its content and use are imposed any restrictions.
(4) specific embodiment
Embodiment 1.
80mg polifeprosan (to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) is 20: 80) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 10mg ametycin and 7-hydroxy-star shaped spore native, shake up the back contains 10% ametycin and 10%7-hydroxy-star shaped spore native with spray drying method for preparation injectable microsphere again.Then microsphere is suspended in the normal saline that contains 15% mannitol, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 2.
The method step that is processed into slow releasing injection is identical with embodiment 1, but different is that contained anticancer effective component and percentage by weight thereof are:
(1) 2 30 aclarubicin, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star;
(2) 7-hydroxy-star shaped spore native of 2-40%, 7-O-alkyl-star shaped spore native, the beta-methoxy-star shaped spore native, alkyl phosphate choline, hexa-decyl choline phosphate, octadecyl-(1, the 1-dimethyl-4-piperidine) phosphate, 1-O-six decyls-2-O-methyl-rac-glyceryl-3-phosphocholine, 1-O-octadecyl-2-O-methyl-rac-glyceryl-3-phosphocholine, 1-O-octadecyl-2-O-methyl-sn-glyceryl-3-phosphocholine, inositolpolyphosphates, cyclosporin A, the basic phosphocholine of 14 (alkane), six certain herbaceous plants with big flowers base phosphoric acid (N-N-N-trimethyl) hexanol amine, D 19391 or octadecyl-[2-(N-methyl piperidine) ethyl]-phosphate; Or
(3) aclarubicin of 2-30%, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, 7-hydroxy-star shaped spore native of teloxantrone or chlorine assistant star and 2-40%, 7-O-alkyl-star shaped spore native, the beta-methoxy-star shaped spore native, alkyl phosphate choline, hexa-decyl choline phosphate, octadecyl-(1, the 1-dimethyl-4-piperidine) phosphate, 1-O-six decyls-2-O-methyl-rac-glyceryl-3-phosphocholine, 1-O-octadecyl-2-O-methyl-rac-glyceryl-3-phosphocholine, 1-O-octadecyl-2-O-methyl-sn-glyceryl-3-phosphocholine, inositolpolyphosphates, cyclosporin A, the basic phosphocholine of 14 (alkane), six certain herbaceous plants with big flowers base phosphoric acid (N-N-N-trimethyl) hexanol amine, D 19391 or octadecyl-[2-(N-methyl piperidine) ethyl]-phosphatic combination.
Embodiment 3.
With 70mg molecular weight peak value 65000 polylactic acid (PLGA, 75: 25) put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 15mg valrubicin and 15mg7-ethyl-10-hydroxycamptothecine, shake up the dry organic solvent of removing of final vacuum again.Dried pastille solid composite freezing and pulverizing is made the micropowder that contains 10% valrubicin and 10%7-ethyl-10-hydroxycamptothecine, be suspended in then in the normal saline that contains 1.5% sodium carboxymethyl cellulose, make corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 20-35 days, is about 35-50 days at the subcutaneous drug release time of mice.
Embodiment 4
The method step that is processed into slow releasing injection is identical with embodiment 3, but different is that contained anticancer effective component and percentage by weight thereof are:
(1) imidazopyrazine of 2-40%, imidazopyridine, wortmannin, .alpha.-5:6-benzopyran, 2-(morphol-4-yl)-.alpha.-5:6-benzopyran-4-base, 2-(4-Lin Ji)-8-phenylchromone, 1-(2-hydroxyl-4-morphol-4-base-phenyl)-ethano-), inhibitors of kinases, vanillin, 2-aminopurine, 7-ethyl-10-hydroxycamptothecine, phenylbutyric acid salt, methylamine, methoxamine, hydroxylamine, minocycline, the O-hydroxylamine, O-methyl hydroxylamine or O-δ-ammonia oxygen-butyl hydroxylamine; Or
(2) aclarubicin of 2-30%, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, the imidazopyrazine of teloxantrone or chlorine assistant star and 2-40%, imidazopyridine, wortmannin, .alpha.-5:6-benzopyran, 2-(morphol-4-yl)-.alpha.-5:6-benzopyran-4-base, 2-(4-Lin Ji)-8-phenylchromone, 1-(2-hydroxyl-4-morphol-4-base-phenyl)-ethano-), inhibitors of kinases, vanillin, 2-aminopurine, 7-ethyl-10-hydroxycamptothecine, phenylbutyric acid salt, methylamine, methoxamine, hydroxylamine, minocycline, the O-hydroxylamine, the combination of O-methyl hydroxylamine or O-δ-ammonia oxygen-butyl hydroxylamine.
Embodiment 5.
(EVAc) puts into container with the 70mg ethylene vinyl acetate copolymer, after adding 100 milliliters of dichloromethane dissolving mixings, add 20 milligrams of aclarubicins and 10 milligrams of benzimidazoles, shake up the back contains 20% aclarubicin and 10% benzimidazole with spray drying method for preparation injectable microsphere again.Then microsphere is suspended in the injection that contains the 5-15% sorbitol, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 6.
The method step that is processed into slow releasing injection is identical with embodiment 5, but different is that contained anticancer effective component is:
(1) the 3-aminobenzamide of 2-40%, Benzoylamide, 3,4-dihydro methoxy isoquinolin-1 (2H)-Benzoylamide, AG14361, the poly polymerase inhibitor, the amino 2-aromatic radical benzimidazole-4-carboxamides BZ1-6 that replaces, benzimidazole-4-carboxamides BZ1-6, tricyclic lactam hydrogen sulfide, three ring benzimidazole carboxylic acid amides, benzimidazole, 1H-three ring benzimidazole carboxylic acid amides, 2-aromatic radical-1H-benzimidazole-4-carboxamides BZ1-6,2-phenyl-1H-benzimidazole-4-carboxamides BZ1-6,2-(4-hydroxymethyl phenyl)-1H-benzimidazole-4-carboxamides BZ1-6,2-(3-anisyl)-1H-benzimidazole-4-carboxamides BZ1-6,8-hydroxy-2-methyl quinazolinone or 2-(4-hydroxyphenyl) benzimidazole-4-carboxamides BZ1-6; Or
(2) aclarubicin of 2-30%, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, the 3-aminobenzamide of teloxantrone or chlorine assistant star and 2-40%, Benzoylamide, 3,4-dihydro methoxy isoquinolin-1 (2H)-Benzoylamide, AG14361, the poly polymerase inhibitor, the amino 2-aromatic radical benzimidazole-4-carboxamides BZ1-6 that replaces, benzimidazole-4-carboxamides BZ1-6, tricyclic lactam hydrogen sulfide, three ring benzimidazole carboxylic acid amides, benzimidazole, 1H-three ring benzimidazole carboxylic acid amides, 2-aromatic radical-1H-benzimidazole-4-carboxamides BZ1-6,2-phenyl-1H-benzimidazole-4-carboxamides BZ1-6,2-(4-hydroxymethyl phenyl)-1H-benzimidazole-4-carboxamides BZ1-6,2-(3-anisyl)-1H-benzimidazole-4-carboxamides BZ1-6, the combination of 8-hydroxy-2-methyl quinazolinone or 2-(4-hydroxyphenyl) benzimidazole-4-carboxamides BZ1-6.
Embodiment 7.
70mg polifeprosan (to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) is 20: 80) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 20mg darubicin and 10mg DL-Buthionine-(S,R)-sulfoximine BSO, shake up the back contains 20% darubicin and 10% DL-Buthionine-(S,R)-sulfoximine BSO with spray drying method for preparation injectable microsphere again.Microsphere is suspended in the normal saline that contains 1.5% sodium carboxymethyl cellulose and 0.5% Tween 80 then, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 8.
The method step that is processed into slow releasing injection is identical with embodiment 7, but different is that contained anticancer effective component is:
(1) glutathione bisulphide of 2-40%, tetramethylthiuram disulfide, aminotriazole(ATA), DL-Buthionine-(S,R)-sulfoximine BSO, cavatic acid, S-hexyl glutathion, new podophyllotoxin; Or
(2) aclarubicin of 2-30%, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, the glutathione bisulphide of teloxantrone or chlorine assistant star and 2-40%, tetramethylthiuram disulfide, aminotriazole(ATA), DL-Buthionine-(S,R)-sulfoximine BSO, cavatic acid, S-hexyl glutathion, new podophyllotoxin, N-[2-(dimethylamino) ethyl] acridine-4-carboxylic acid amides, 6-[2-(dimethylamino) ethylamino-]-3-hydroxyl-7H-indenols [2,1-c] chinol-7-dihydrochloride, two-dioxo piperazine propane, the combination of Exatecan mesylate or TAN-1518.
Embodiment 9
70mg polifeprosan (to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) is 20: 80) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 20mg doxorubicin and 10mgO4-benzyl folic acid, shake up the back contains 20% doxorubicin and 10%O4-benzyl folic acid with spray drying method for preparation injectable microsphere again.Then microsphere is suspended in the normal saline that contains 1.5% sodium carboxymethyl cellulose and 15% sorbitol and 0.2% Tween 80, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 10
The method step that is processed into slow releasing injection is identical with embodiment 9, but different is that contained anticancer effective component is:
(1) the O4-benzyl folic acid, 2 of 10-40%, 4,5-triamido-6-benzyloxy pyrimidine, 2,4-diaminourea-6-benzyloxy-5-nitroso-group pyrimidine, 2,4-diaminourea-6-benzyloxy-5-bromo pyrimidine, 2-amino-4-benzyloxy-5-nitro-pyrimidine, 2-amino-4-benzyloxy-6-methyl-5-nitro pyrimidine, 2,4-diaminourea-6-benzyloxy-s-triazine or 2-amino-O4-benzyl pteridine; Or
(2) 10-30% aclarubicin, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, the O4-benzyl folic acid of teloxantrone or chlorine assistant star and 10-40%, 2,4,5-triamido-6-benzyloxy pyrimidine, 2,4-diaminourea-6-benzyloxy-5-nitroso-group pyrimidine, 2,4-diaminourea-6-benzyloxy-5-bromo pyrimidine, 2-amino-4-benzyloxy-5-nitro-pyrimidine, 2-amino-4-benzyloxy-6-methyl-5-nitro pyrimidine, 2, the combination of 4-diaminourea-6-benzyloxy-s-triazine or 2-amino-O4-benzyl pteridine.
Embodiment 11
70mg polifeprosan (to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) is 20: 80) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 10mg7-hydroxy-star shaped spore native and 20mg doxorubicin, shake up the back contains 10%7-hydroxy-star shaped spore native and 20% doxorubicin with spray drying method for preparation injectable microsphere again.Then microsphere is made corresponding sustained-release implant through pressed disc method.The drug release time of this sustained-release implant in external normal saline is 10-15 days, is about 30-40 days at the subcutaneous drug release time of mice.
Embodiment 12
The method step that is processed into sustained-release implant is identical with embodiment 11, but different is that contained anticancer effective component is:
20% amycin, epirubicin, ametycin, actinomycin D, nocardin, nocardorubin., aclarubicin, darubicin, Diacetoxysciroenol, clarithromycin, 9-[4-(N-Methylacetamido)anilino, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, 7-hydroxy-the star shaped spore native of teloxantrone or chlorine assistant star and 10%, 7-O-alkyl-star shaped spore native, the beta-methoxy-star shaped spore native, alkyl phosphate choline, hexa-decyl choline phosphate, octadecyl-(1, the 1-dimethyl-4-piperidine) phosphate, 1-O-six decyls-2-O-methyl-rac-glyceryl-3-phosphocholine, 1-O-octadecyl-2-O-methyl-rac-glyceryl-3-phosphocholine, 1-O-octadecyl-2-O-methyl-sn-glyceryl-3-phosphocholine, inositolpolyphosphates, cyclosporin A, the basic phosphocholine of 14 (alkane), six certain herbaceous plants with big flowers base phosphoric acid (N-N-N-trimethyl) hexanol amine, D 19391 or octadecyl-[2-(N-methyl piperidine) ethyl]-phosphatic combination.
Embodiment 13
With 70mg molecular weight peak value 80000 polylactic acid (PLGA, 50: 50) put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 10mg oxaliplatin and the new podophyllotoxin of 20mg, shake up the back contains 10% oxaliplatin and 20% new podophyllotoxin with spray drying method for preparation injectable microsphere again.Then microsphere is made corresponding sustained-release implant through pressed disc method.The drug release time of this sustained-release implant in external normal saline is 25-30 days, is about 35-50 days at the subcutaneous drug release time of mice.
Embodiment 14
Be processed into the method step and the embodiment 11 of sustained-release implant, 13 is identical, but different is that contained anticancer effective component is: 10% amycin, epirubicin, ametycin, actinomycin D, aclarubicin, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, the glutathione bisulphide of teloxantrone or chlorine assistant star and 20%, tetramethylthiuram disulfide, aminotriazole(ATA), DL-Buthionine-(S,R)-sulfoximine BSO, cavatic acid, S-hexyl glutathion, new podophyllotoxin, the combination of Exatecan mesylate or TAN-1518.
Embodiment 15
The method step that is processed into slow releasing agent is identical with embodiment 1-14, but different is used slow-release auxiliary material is one of following or its combination:
A) polylactic acid, molecular weight peak value are 10000-30000,300000-60000,60000-100000 or 100000-150000;
B) copolymer of polyglycolic acid and hydroxyacetic acid, wherein, the ratio of polyglycolic acid and hydroxyacetic acid is 50-95: 50-50, the molecular weight peak value is 10000-30000,300000-60000,60000-100000 or 100000-150000;
C) ethylene vinyl acetate copolymer;
D) polifeprosan, to carboxy phenyl propane: the certain herbaceous plants with big flowers diacid is 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40;
E) bis-fatty acid and decanedioic acid copolymer;
F) poly-(erucic acid dimer-decanedioic acid);
G) poly-(fumaric acid-decanedioic acid);
H) xylitol, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, gelatin or white tempera.
Embodiment 16
The method step that is processed into slow releasing injection is identical with embodiment 1-15, but different is used suspending agent is respectively one of following or its combination:
A) 0.5-3.0% carboxymethyl cellulose (sodium);
B) 5-15% mannitol;
C) 5-15% sorbitol;
D) 0.1-1.5% surfactant;
E) 0.1-0.5% polysorbas20.
Embodiment 17
The method step that is processed into slow releasing injection is identical with embodiment 11-15, but different is that contained anticancer effective component is:
(a) aclarubicin of 2-30%, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star;
(b) the O4-benzyl folic acid, 2 of 2-40%, 4,5-triamido-6-benzyloxy pyrimidine, 2,4-diaminourea-6-benzyloxy-5-nitroso-group pyrimidine, 2,4-diaminourea-6-benzyloxy-5-bromo pyrimidine, 2-amino-4-benzyloxy-5-nitro-pyrimidine, 2-amino-4-benzyloxy-6-methyl-5-nitro pyrimidine, 2,4-diaminourea-6-benzyloxy-s-triazine or 2-amino-O4-benzyl pteridine;
(c) aclarubicin of 2-30%, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, the O4-benzyl folic acid of teloxantrone or chlorine assistant star and 2-40%, 2,4,5-triamido-6-benzyloxy pyrimidine, 2,4-diaminourea-6-benzyloxy-5-nitroso-group pyrimidine, 2,4-diaminourea-6-benzyloxy-5-bromo pyrimidine, 2-amino-4-benzyloxy-5-nitro-pyrimidine, 2-amino-4-benzyloxy-6-methyl-5-nitro pyrimidine, 2, the combination of 4-diaminourea-6-benzyloxy-s-triazine or 2-amino-O4-benzyl pteridine;
(d) 7-hydroxy-star shaped spore native of 2-40%, 7-O-alkyl-star shaped spore native, beta-methoxy-star shaped spore native, alkyl phosphate choline or hexa-decyl choline phosphate;
(e) combination of 7-hydroxy-star shaped spore native, 7-O-alkyl-star shaped spore native, beta-methoxy-star shaped spore native, alkyl phosphate choline or the hexa-decyl choline phosphate of the aclarubicin of 2-30%, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star and 2-40%;
(f) imidazopyrazine of 2-40%, imidazopyridine, wortmannin, .alpha.-5:6-benzopyran, 2-(morphol-4-yl)-.alpha.-5:6-benzopyran-4-base, 2-(4-Lin Ji)-8-phenylchromone, 1-(2-hydroxyl-4-morphol-4-base-phenyl)-ethano-), inhibitors of kinases, vanillin, 2-aminopurine, 7-ethyl-10-hydroxycamptothecine, phenylbutyric acid salt, methylamine, methoxamine, hydroxylamine, minocycline, the O-hydroxylamine, O-methyl hydroxylamine or O-δ-ammonia oxygen-butyl hydroxylamine;
(g) aclarubicin of 2-30%, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, the imidazopyrazine of teloxantrone or chlorine assistant star and 2-40%, imidazopyridine, wortmannin, .alpha.-5:6-benzopyran, 2-(morphol-4-yl)-.alpha.-5:6-benzopyran-4-base, 2-(4-Lin Ji)-8-phenylchromone, 1-(2-hydroxyl-4-morphol-4-base-phenyl)-ethano-), inhibitors of kinases, vanillin, 2-aminopurine, 7-ethyl-10-hydroxycamptothecine, phenylbutyric acid salt, methylamine, methoxamine, hydroxylamine, minocycline, the O-hydroxylamine, the combination of O-methyl hydroxylamine or O-δ-ammonia oxygen-butyl hydroxylamine;
(h) aclarubicin of 2-40%, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, the 3-aminobenzamide of teloxantrone or chlorine assistant star and 2-40%, Benzoylamide, 3,4-dihydro methoxy isoquinolin-1 (2H)-Benzoylamide, AG14361, the poly polymerase inhibitor, the amino 2-aromatic radical benzimidazole-4-carboxamides BZ1-6 that replaces, benzimidazole-4-carboxamides BZ1-6, tricyclic lactam hydrogen sulfide, three ring benzimidazole carboxylic acid amides, benzimidazole, 1H-three ring benzimidazole carboxylic acid amides, 2-aromatic radical-1H-benzimidazole-4-carboxamides BZ1-6,2-phenyl-1H-benzimidazole-4-carboxamides BZ1-6,2-(4-hydroxymethyl phenyl)-1H-benzimidazole-4-carboxamides BZ1-6,2-(3-anisyl)-1H-benzimidazole-4-carboxamides BZ1-6, the combination of 8-hydroxy-2-methyl quinazolinone or 2-(4-hydroxyphenyl) benzimidazole-4-carboxamides BZ1-6;
(i) 2-40% aminotriazole(ATA), DL-Buthionine-(S,R)-sulfoximine BSO, cavatic acid, S-hexyl glutathion, new podophyllotoxin, Exatecan mesylate or TAN-1518; Or
(j) combination of the aminotriazole(ATA) of the aclarubicin of 2-30%, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star and 2-40%, DL-Buthionine-(S,R)-sulfoximine BSO, cavatic acid, S-hexyl glutathion, new podophyllotoxin, Exatecan mesylate or TAN-1518.
Above embodiment only is used for explanation, and is not limitation application of the present invention.
The present invention disclosed and the protection the content see claim.

Claims (2)

1. a compound anti-cancer sustained-release antibiotic preparation is slow releasing injection, is grouped into by following one-tenth:
(1) anticancer effective component is 10% ametycin and 10%7-hydroxy-star shaped spore native, and slow-release auxiliary material is to carboxy phenyl propane: decanedioic acid is 20: 80 a polifeprosan, and solvent is the normal saline that contains 15% mannitol;
(2) anticancer effective component is 20% aclarubicin and 10% benzimidazole, and slow-release auxiliary material is an ethylene vinyl acetate copolymer, and solvent is the injection that contains the 5-15% sorbitol;
(3) anticancer effective component is 20% darubicin and 10% DL-Buthionine-(S,R)-sulfoximine BSO, and slow-release auxiliary material is to carboxy phenyl propane: decanedioic acid is 20: 80 a polifeprosan, and solvent is the normal saline of 1.5% sodium carboxymethyl cellulose and 0.5% Tween 80; Or
(4) anticancer effective component is 20% doxorubicin and 10%04-benzyl folic acid, and slow-release auxiliary material is to carboxy phenyl propane: decanedioic acid is 20: 80 a polifeprosan, and solvent is the normal saline of 1.5% sodium carboxymethyl cellulose and 15% sorbitol and 0.2% Tween 80.
2. the slow-releasing anticarcinogen injection according to claim 1, it is characterized in that slow-releasing anticarcinogen injection is used to prepare the suspensoid injectio that treatment originates from cancer, sarcoma or the carcinosarcoma of people and animal brain, central nervous system, kidney, liver, gallbladder, incidence, oral cavity, thyroid, skin, mucosa, body of gland, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, uterus, ovary, endometrium, cervix uteri, prostate, bladder, colon or rectum former or secondary, in tumor or tumor week drug administration by injection.
CN200610200171A 2006-02-24 2006-02-24 Compound recipe anti-cancer drugs slow release agent comprising anticancer antibiotics and synergist thereof Expired - Fee Related CN1923171B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN200610200171A CN1923171B (en) 2006-02-24 2006-02-24 Compound recipe anti-cancer drugs slow release agent comprising anticancer antibiotics and synergist thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200610200171A CN1923171B (en) 2006-02-24 2006-02-24 Compound recipe anti-cancer drugs slow release agent comprising anticancer antibiotics and synergist thereof

Publications (2)

Publication Number Publication Date
CN1923171A CN1923171A (en) 2007-03-07
CN1923171B true CN1923171B (en) 2010-05-19

Family

ID=37816115

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200610200171A Expired - Fee Related CN1923171B (en) 2006-02-24 2006-02-24 Compound recipe anti-cancer drugs slow release agent comprising anticancer antibiotics and synergist thereof

Country Status (1)

Country Link
CN (1) CN1923171B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104109247B (en) * 2013-01-15 2018-03-02 张雅珍 A kind of preparation and use of the polymer containing Doxorubicin structure
US9708359B2 (en) 2015-08-06 2017-07-18 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof
US11111264B2 (en) 2017-09-21 2021-09-07 Chimerix, Inc. Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1079385A (en) * 1992-06-01 1993-12-15 丛繁滋 The preparation method of liposome of anticancer medicine
CN1561988A (en) * 2004-03-18 2005-01-12 山东居仁生物医药技术研究所 Method for preparing taxol micro ball anti-cancer medicine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1079385A (en) * 1992-06-01 1993-12-15 丛繁滋 The preparation method of liposome of anticancer medicine
CN1561988A (en) * 2004-03-18 2005-01-12 山东居仁生物医药技术研究所 Method for preparing taxol micro ball anti-cancer medicine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
郭艳霜.聚乳酸载药纳米微球的制备及其对脑胶质瘤的抑制研究.天津大学材料科学与工程学院申请硕士学位论文.2004,1,40,70. *

Also Published As

Publication number Publication date
CN1923171A (en) 2007-03-07

Similar Documents

Publication Publication Date Title
CN101433520A (en) Anticancer sustained-release agent containing epothilone
CN1969816A (en) Anticancer sustained release agent containing epothilone
CN101336899A (en) Anticancer sustained-released injection containing taxane
CN1923171B (en) Compound recipe anti-cancer drugs slow release agent comprising anticancer antibiotics and synergist thereof
CN101502484B (en) Glucocorticosteroid and chemotherapy medicament carried by anticancer sustained-release agent
CN101380303A (en) Anti-cancer medicine sustained-released injection loaded with platinum compound and synergist thereof
CN100500215C (en) Slow-released injection containing methotrexate and its synergist
CN101637444B (en) Anti-cancer drug slow release injection containing gemcitabine
CN1923173B (en) Anti-cancer drugs slow release agent comprising anticancer antibiotics and synergist thereof
CN100563711C (en) A kind of slow-releasing anticarcinogen injection
CN101427994B (en) Gemcitabine-containing anti-cancer medicine sustained-release injection
CN1969825A (en) Sustained release agent containing fluorouracil and synergist thereof
CN100563710C (en) The anticancer medicine slow-release preparation containing that contains pyrimidine analogue
CN100500214C (en) Slow-released anticancer medicine injection
CN101292956A (en) Sustained-release injection containing methotrexate and its synergistic agent
CN101244033A (en) Sustained-release agent containing taxone and its synergistic agent
CN100464785C (en) Anti-cancer drug slow release injection and uses thereof
CN1969824A (en) Anticancer sustained release agent containing fluorouracil and synergist thereof
CN1969823A (en) Sustained release agent containing fluorouracil and synergist thereof
CN101380306A (en) Compound platinum medicine sustained-release agent
CN101254166A (en) An anticancer sustained release injection carrying clorfarabine and its synergist
CN101380297A (en) Compound platinum medicine sustained-release agent
CN101380304A (en) Anticancer sustained-released formulation loaded with blood vessel inhibitor and synergist thereof
CN101292955A (en) Sustained-release injection containing fluorouracil synergistic agent and preparation method thereof
CN101292954A (en) Anti-cancer medicament sustained-release injection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750

Patentee after: Jinan Kangquan Medicine Sci. & Tech. Co., Ltd.

Address before: 206, room 2, building 19, Pioneer Park, No. 250100 Huaneng Road, Shandong, Ji'nan

Patentee before: Jinan Kangquan Medicine Sci. & Tech. Co., Ltd.

ASS Succession or assignment of patent right

Owner name: SHANDONG LANJIN BIOENGINEERING CO., LTD.

Free format text: FORMER OWNER: JINAN KANGQUAN MEDICINE SCI. + TECH. CO., LTD.

Effective date: 20120807

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20120807

Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750

Patentee after: Shandong Lanjin Pharmaceuticals Co., Ltd.

Address before: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750

Patentee before: Jinan Kangquan Medicine Sci. & Tech. Co., Ltd.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100519

Termination date: 20160224

CF01 Termination of patent right due to non-payment of annual fee